Phase I study of cetuximab plus U3-1565 in colorectal cancer with resistance to anti-EGFR antibody

ABSTRACT: Interventions: Level1 First dose Cetuximab: 400 mg/m2 div day1 U3-1565: 24 mg/kg div day1 From second dose on Cetuximab: 250 mg/m2 div. day1,8 U3-1565: 16 mg/kg div day1 q2w Level0 First dose Cetuximab: 400 mg/m2 div day1 U3-1565: 16 mg/kg div day1 From second dose on Cetuximab: 250 mg/m2 div day1,8 U3-1565: 12 mg/kg div day1,8 q2w Primary outcome(s): Proportion of DLT(Dose limiting toxicity) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2628359 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR